Presentations Archives - Ractigen Therapeutics

Presentations RAG-01 Presentation

Development and Clinical Progress of RAG-01, a Novel saRNA Targeting p21 for Non-Muscle Invasive Bladder Cancer Treatment. (Abstract)

Event: 2024 Oligonucleotide Therapeutics Society Meeting (Montreal) View Abstract

ractigenOctober 11, 2024

Presentations

Therapeutic Development of saRNA for Duchenne Muscular Dystrophy by Targeted Activation of Utrophin (Poster)

Event: 2024 TIDES Asia Conference (Tokyo Japan) View Poster

ractigenMarch 21, 2024

Presentations

Therapeutic Development of saRNA for Duchenne Muscular Dystrophy by Targeted Activation of Utrophin (Poster)

Event: 2023 Annual OTS Conference (Barcelona Spain) View Poster

EnvisionNovember 2, 2023

Presentations

SCAD: a platform technology for CNS delivery of duplex RNA by intrathecal administration (Poster)

Event: 2023 Annual OTS Conference (Barcelona Spain) View Poster

EnvisionNovember 2, 2023

Presentations RAG-01 Presentation

Preclinical development of RAG1-40-31L: A novel small activating RNA-lipid conjugate targeting tumor suppressor gene p21 for treatment of non-muscle invasive bladder cancer. (Abstract)

Event: 2023 American Society of Clinical Oncology Meeting (Chicago) View Abstract

EnvisionJune 7, 2023

Presentations RAG-17 Presentation

siRNA-ACO is a convenient phosphoramidite-based conjugate that enables RNAi in the CNS via local administration with superior efficacy in the treatment of ALS rodent models (Poster)

Event: 2023 TIDES USA (San Diego) View Poster

EnvisionMay 12, 2023

Presentations RAG-17 Presentation

Local administration of a novel siRNA conjugate (siRNA-ACO) into the CNS extends survival and improves motor function in the SOD1G93A mouse model for ALS (Poster)

Event: 2023 TIDES ASIA (Kyoto, Japan) View Poster

EnvisionMarch 10, 2023

© 2025 Ractigen Therapeutics. All Rights Reserved. Privacy Policy Terms